Prosecution Insights
Last updated: November 12, 2026
Application No. 18/896,139

Plants with Improved Growth

Non-Final OA §103§112
Filed
Sep 25, 2024
Priority
Dec 04, 2017 — SE 1751493-6 +2 more
Examiner
LOGSDON, CHARLES
Art Unit
1662
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
SweTree Technologies AB
OA Round
1 (Non-Final)
72%
Grant Probability
Favorable
1-2
OA Rounds
83%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
398 granted / 552 resolved
+12.1% vs TC avg
Moderate +11% lift
Without
With
+10.8%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
21 currently pending
Career history
572
Total Applications
across all art units

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Acknowledgment is made of applicant’s claim for foreign priority under 35 U.S.C. 119 (a)-(d). Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Election/Restrictions Applicant's election with traverse of the species of SEQ ID NO:4, 12, 24, 32 and 39 in the reply filed on 08/06/2026 is acknowledged. The traversal is on the grounds that the groups of List 1 and List 2 are all orthologous TF0132 genes and encoded proteins. This is found persuasive and as such the species election requirement is withdrawn. Similarly, although the promoters of List 3 are structurally diverse, Examiner finds Applicant’s arguments persuasive and the species election requirement with regard to List 3 is also withdrawn. Status of the Claims Claims 28-41 are pending. Claims 28-41 are examined herein. Claim Objections Claim 39 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 29, 40 and 41 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicant claims a coding sequence encoding a TF0132 gene, operably linked to a promoter, wherein the promoter is pEC1, pEL1.1, pEA1, pEA2, pECO2, pEA3, pEA4, pECO1, or a promoter that has the same, or essentially the same, capability of initiating transcription of a coding sequence when operably linked to the coding sequence. Applicant describes the promoters pEC1, pEL1.1, pEA1, pEA2, pECO2, pEA3, pEA4, pECO1 by virtue of sequence identifiers. Applicant does not adequately describe the genus of promoters that has the same, or essentially the same, capability of initiating transcription of a coding sequence relative to the described promoters. Each of the promoters has a specific expression pattern and the genus encompasses any nucleic acid sequence that would produce an equivalent expression pattern. Koo, Hyunjin, et al. "Identification and application of promoters and terminators for plant synthetic biology." Molecules and Cells (2025): 100273 teaches that while promoter identification and synthetic promoter design has advanced considerably, much work remains in identifying those structures that cause specific expression patterns in plants. The instant disclosure fails to remedy the dearth of description of the structure-function relationship between promoter sequences and expression patterns in the prior art. As such, Applicant cannot be deemed to have been in possession of the claimed genus of promoters at the time of filing. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 28-41 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 28 and 41 recite in relevant part “the nucleotide sequence of SEQ ID NO: 24, 85, 87, 89, 91, 115, 117, 119, 121, 123, or 125, or an ortholog thereof, or (ii) a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 4, 84, 86, 88, 90, 114, 116, 118, 120, 122, 124, or an ortholog thereof”. The metes and bounds of the claims are unclear because the claim encompasses “orthologs” of TF0132 genes and polypeptides. TF0132 is an alphanumeric designation applied to a subset of WRKY transcription factors. “TF0132” is not a term widely recognized in the art, never appearing the non-patent literature. As such, it is unclear what “orthologs” of TF0132 encompass. The Specification provides as follows: “By “ortholog” or “orthologous polypeptide” is meant a polypeptide expressed by evolutionarily related genes that have a similar nucleic acid sequence, where the polypeptide has similar functional properties. Orthologous genes are structurally related genes, from different species, derived by a speciation event from an ancestral gene.” It is unclear what the functions of TF0132-like genes/polypeptides must be to be considered “orthologs”. It is unclear if the growth phenotypes described in the Specification are part of the normal function of the genes. As such, the scope of “orthologs” is undefined and unclear. Dependent claims are rejected as a function of their inherency. Claim 40 recites in relevant part: “A method of making the genetically modified plant of claim 28, the method comprising: a) providing a suitable part of a plant; b) providing a heterologous nucleic acid construct comprising a promoter operably linked to a coding sequence encoding a TF0132 gene”. However, Claim 28 recites in relevant part that “a TF0132 gene, comprising: (i) a nucleotide sequence as set forth in SEQ ID NO: 24, 85, 87, 89, 91, 115, 117, 119, 121, 123 or 125, or an ortholog thereof; or (ii) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 4, 84, 86, 88, 90, 114, 116, 118, 120, 122, 124, or an ortholog thereof”. It is unclear if Claim 40 includes all of the limitations of Claim 28, as Claim 40 recites “a TF0132 gene”. The claim should recite “the TF0132 gene” if the intent is to require the limitations of Claim 28. Otherwise, Claim 40 would draw a rejection under 35 USC 112(d) for failure to further limit the claim from which it depends. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 28 and 30-38 are rejected under 35 U.S.C. 103 as being unpatentable over Hertzberg (US 20110016550 A1). Applicant claims as follows: 28. (New) A genetically modified plant comprising a heterologous nucleic acid construct comprising a promoter operably linked to a coding sequence encoding a TF0132 gene, comprising: (i) a nucleotide sequence as set forth in SEQ ID NO: 24, 85, 87, 89, 91, 115, 117, 119, 121, 123 or 125, or an ortholog thereof; or (ii) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 4, 84, 86, 88, 90, 114, 116, 118, 120, 122, 124, or an ortholog thereof, wherein the promoter is selected from the group consisting of: a promoter preferentially or specifically expressed in phloem tissue of the plant, a promoter preferentially or specifically expressed in meristematic tissue of the plant, a promoter preferentially or specifically expressed in xylem tissue of the plant, and a promoter preferentially or specifically expressed in root tissue of the plant. 30. (New) The genetically modified plant of claim 28, wherein the promoter preferentially or specifically expressed in meristematic tissue of the plant is preferentially or specifically expressed in at least one of cambium, vascular meristematic tissue, and shoot meristem tissue of the plant. 31. (New) The genetically modified plant of claim 30, wherein the promoter is not significantly expressed in at least one of mature xylem, stem phloem, whole leaves, whole roots, and bark of the plant. 32. (New) The genetically modified plant of claim 28, wherein the TF0132 gene is from Eucalyptus grandis,Zea Mays, Populus trichocarpa, or Arabidopsis thaliana. 33. (New) The genetically modified plant of claim 28, comprising a modified trait as compared to a wild-type plant of the same species, wherein the modified trait is plant yield, plant height, plant width, stem volume, stem dry weight, bark dry weight, wood density, leaf dry weight, average internode length, or number of internodes. 34. (New) The genetically modified plant of claim 33, wherein the modified trait is increased as compared to a wild-type plant of the same species when the plants are grown under identical field conditions for a period of at least one year. 35. (New) The genetically modified plant of claim 28, wherein the plant is a woody plant. 36. (New) The genetically modified plant of claim 28, wherein the plant is a hardwood plant. 37. (New) The genetically modified plant of claim 28, wherein the plant is of the genus Eucalyptus or Populus. 38. (New) The genetically modified plant of claim 28, wherein the plant is a crop plant. Hertzberg teaches the transformation of hybrid (Populus tremula x P. tremuloides) aspen (a hardwood tree) with 35S CaMV expression constructs, at least one of which comprised a nucleic acid sequence of Hertzberg SEQ ID NO:7, which encodes Hertzberg SEQ ID NO:20 (Table B, ¶ 211-213). Hertzberg teaches that the resultant hybrid aspen trees exhibited significantly higher total height and growth rate compared to controls. (¶ 0259). Hertzberg SEQ ID NO:7, which encodes Hertzberg SEQ ID NO:20 is identified as a TF0132 gene from Populus trichocarpa and as such reasonably reads on an ortholog of a TF0132 in the instant claims. (Table B). Hertzberg does not teach that the TF0132 gene is expressed from a promoter that is selected from the group consisting of: a promoter preferentially or specifically expressed in phloem tissue of the plant, a promoter preferentially or specifically expressed in meristematic tissue of the plant, a promoter preferentially or specifically expressed in xylem tissue of the plant, and a promoter preferentially or specifically expressed in root tissue of the plant as a single embodiment, and as such, no 102 rejection is made. However, the combined teachings of Hertzberg render the claims obvious. Hertzberg further teaches that particularly relevant tissue specific promoters to be used with the invention include promoter sequences specifically expressed or active in the xylem forming tissue in a plant. Examples of such promoters are the Lmp1, Lmx2, Lmx3, Lmx4 and Lmx5 promoters. (¶ 0078). It would have been prima facie obvious to use a promoter such as Lmp1, Lmx2, Lmx3, Lmx4 and Lmx5, which direct expression in xylem forming tissues with the TF0132 gene also taught by Hertzberg. One having ordinary skill in the art would have been motivated to do so because Hetzberg teaches that such promoters are of particular relevance to the invention. One having ordinary skill in the art would have had a reasonable expectation of success because the use of known promoters in expression systems is routine and conventional in the art. Hertzberg does not teach that the TF0132 gene is expressed in a crop plant as a single embodiment, and as such, no 102 rejection is made. However, the combined teachings of Hertzberg render the claims obvious. Hertzberg further teaches that plants that can be used with the invention include crop plants. (¶ 0123). It would have been prima facie obvious to express the TF0132 gene in a crop plant. One having ordinary skill in the art would have been motivated to do so because Hetzberg explicitly teaches that the invention can be used with crop plants. One having ordinary skill in the art would have had a reasonable expectation of success because the use expression constructs in crops is routine and conventional in the art. As such, the claimed inventions are obvious in view of the teachings of the prior art. Conclusion No claims are allowed. Claims 29, 39-41 are deemed to be free of the prior art. The closest prior art is Hertzberg (US 20110016550 A1), the teachings of which are set forth previously herein. The prior art does not disclose, teach or otherwise render obvious the combination of TF0132 WRKY genes and the listed promoters. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARLES A LOGSDON whose telephone number is (571)270-0282. The examiner can normally be reached M-F 8:30 - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bratislav Stankovic can be reached at (571) 270-0305. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARLES LOGSDON/Primary Examiner, Art Unit 1662
Read full office action

Prosecution Timeline

Sep 25, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778063
ALFALFA VARIETY R0919TF549
2y 8m to grant Granted Nov 03, 2026
Patent 12772944
WATERMELON VARIETY NUN 22102 WMW
2y 7m to grant Granted Oct 27, 2026
Patent 12751413
PEA VARIETY SVQF0508
2y 5m to grant Granted Oct 06, 2026
Patent 12740523
SPINACH HYBRID SVVB2740 AND PARENTS THEREOF
3y 1m to grant Granted Sep 22, 2026
Patent 12716060
NOVEL CRISPR-ASSOCIATED SYSTEMS AND COMPONENTS
3y 4m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
72%
Grant Probability
83%
With Interview (+10.8%)
Low
PTA Risk
Based on 552 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month